APO Research
Talk to an analyst

APO RESEARCH · REPORT

Alpha L-Iduronidase

Compare research editions
View pricing & licenses

Selected research

Industry Research

Alpha L-Iduronidase Industry Research Report 2026

1 January 2026124 pages

Choose your research edition.

Industry ResearchAlpha L-Iduronidase Industry Research Report 2026124 pages · $2,950 USDIndustry Growth & TrendsGlobal Alpha L-Iduronidase Industry Growth and Trends Forecast to 2032109 pages · $3,450 USDMarket StructureGlobal Alpha L-Iduronidase Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032192 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Alpha L-Iduronidase Market Outlook and Growth Opportunities 2026195 pages · $4,250 USDMarket Analysis & ForecastGlobal Alpha L-Iduronidase Market Analysis and Forecast 2026-2032192 pages · $4,950 USD

Market perspective

The global Alpha L-Iduronidase market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.

The North America market for Alpha L-Iduronidase is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.

The Europe market for Alpha L-Iduronidase is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.

Read the full market overview

The Asia Pacific market for Alpha L-Iduronidase is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.

Leading global manufacturers of Alpha L-Iduronidase include ArmaGen Inc, BioStrategies LC, Denali Therapeutics Inc, EdiGene Inc, Gain Therapeutics Inc, Immusoft Corp, JCR Pharmaceuticals Co Ltd, Orchard Therapeutics Plc and Ossianix Inc, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report quantifies the global Alpha L-Iduronidase market in terms of revenue (US$ million) and, where applicable, sales volume (K Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.

It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10).

The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.

Key Companies & Market Share Insights

This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.

Alpha L-Iduronidase Market by Company

ArmaGen Inc

BioStrategies LC

Denali Therapeutics Inc

EdiGene Inc

Gain Therapeutics Inc

Immusoft Corp

JCR Pharmaceuticals Co Ltd

Orchard Therapeutics Plc

Ossianix Inc

Rain Bio Inc

RegenxBio Inc

Tega Therapeutics Inc

Alpha L-Iduronidase Segment by Type

IDUA

EC 3.2.1.76

Alpha L-Iduronidase Segment by Application

Oncology

Dermatology

Immunology

Musculoskeletal Disorders

Alpha L-Iduronidase Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Alpha L-Iduronidase market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Alpha L-Iduronidase and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market

5. This report helps stakeholders to gain insights into which regions to target globally

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Alpha L-Iduronidase.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Research objectives, research methods, data sources, data cross-validation;

Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 3: Detailed analysis of Alpha L-Iduronidase manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.

Chapter 5: Production/output, value of Alpha L-Iduronidase by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.

Chapter 6: Consumption of Alpha L-Iduronidase in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.

Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 11: The main points and conclusions of the report.

More report detail

Tables and figures
List of Tables Table 1. Secondary Sources Table 2. Primary Sources Table 3. Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 4. Market Value Comparison by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 5. Global Alpha L-Iduronidase Volume and Revenue Market Size and CAGR of Manufacturers (2021 Versus 2025) Table 6. Global Alpha L-Iduronidase Sales (K Units) of Manufacturers (2021-2026) Table 7. Global Alpha L-Iduronidase Sales Market Share by Manufacturers (2021-2026) Table 8. Global Alpha L-Iduronidase Revenue of Manufacturers (2021-2026) Table 9. Global Alpha L-Iduronidase Revenue Share by Manufacturers (2021-2026) Table 10. Global Market Alpha L-Iduronidase Average Price (US$/Unit) of Manufacturers (2021-2026) Table 11. Global Alpha L-Iduronidase Industry Ranking, 2024 VS 2025 VS 2026 Table 12. Global Manufacturers of Alpha L-Iduronidase, Manufacturing Sites & Headquarters Table 13. Global Manufacturers of Alpha L-Iduronidase, Product Type & Application Table 14. Global Alpha L-Iduronidase Manufacturers Established Date Table 15. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 16. Global Alpha L-Iduronidase by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 17. Manufacturers Mergers & Acquisitions, Expansion Plans) Table 18. ArmaGen Inc Company Information Table 19. ArmaGen Inc Business Overview Table 20. ArmaGen Inc Alpha L-Iduronidase Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 21. ArmaGen Inc Alpha L-Iduronidase Product Portfolio Table 22. ArmaGen Inc Recent Developments Table 23. BioStrategies LC Company Information Table 24. BioStrategies LC Business Overview Table 25. BioStrategies LC Alpha L-Iduronidase Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 26. BioStrategies LC Alpha L-Iduronidase Product Portfolio Table 27. BioStrategies LC Recent Developments Table 28. Denali Therapeutics Inc Company Information Table 29. Denali Therapeutics Inc Business Overview Table 30. Denali Therapeutics Inc Alpha L-Iduronidase Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 31. Denali Therapeutics Inc Alpha L-Iduronidase Product Portfolio Table 32. Denali Therapeutics Inc Recent Developments Table 33. EdiGene Inc Company Information Table 34. EdiGene Inc Business Overview Table 35. EdiGene Inc Alpha L-Iduronidase Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 36. EdiGene Inc Alpha L-Iduronidase Product Portfolio Table 37. EdiGene Inc Recent Developments Table 38. Gain Therapeutics Inc Company Information Table 39. Gain Therapeutics Inc Business Overview Table 40. Gain Therapeutics Inc Alpha L-Iduronidase Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 41. Gain Therapeutics Inc Alpha L-Iduronidase Product Portfolio Table 42. Gain Therapeutics Inc Recent Developments Table 43. Immusoft Corp Company Information Table 44. Immusoft Corp Business Overview Table 45. Immusoft Corp Alpha L-Iduronidase Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 46. Immusoft Corp Alpha L-Iduronidase Product Portfolio Table 47. Immusoft Corp Recent Developments Table 48. JCR Pharmaceuticals Co Ltd Company Information Table 49. JCR Pharmaceuticals Co Ltd Business Overview Table 50. JCR Pharmaceuticals Co Ltd Alpha L-Iduronidase Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 51. JCR Pharmaceuticals Co Ltd Alpha L-Iduronidase Product Portfolio Table 52. JCR Pharmaceuticals Co Ltd Recent Developments Table 53. Orchard Therapeutics Plc Company Information Table 54. Orchard Therapeutics Plc Business Overview Table 55. Orchard Therapeutics Plc Alpha L-Iduronidase Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 56. Orchard Therapeutics Plc Alpha L-Iduronidase Product Portfolio Table 57. Orchard Therapeutics Plc Recent Developments Table 58. Ossianix Inc Company Information Table 59. Ossianix Inc Business Overview Table 60. Ossianix Inc Alpha L-Iduronidase Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 61. Ossianix Inc Alpha L-Iduronidase Product Portfolio Table 62. Ossianix Inc Recent Developments Table 63. Rain Bio Inc Company Information Table 64. Rain Bio Inc Business Overview Table 65. Rain Bio Inc Alpha L-Iduronidase Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 66. Rain Bio Inc Alpha L-Iduronidase Product Portfolio Table 67. Rain Bio Inc Recent Developments Table 68. RegenxBio Inc Company Information Table 69. RegenxBio Inc Business Overview Table 70. RegenxBio Inc Alpha L-Iduronidase Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 71. RegenxBio Inc Alpha L-Iduronidase Product Portfolio Table 72. RegenxBio Inc Recent Developments Table 73. Tega Therapeutics Inc Company Information Table 74. Tega Therapeutics Inc Business Overview Table 75. Tega Therapeutics Inc Alpha L-Iduronidase Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 76. Tega Therapeutics Inc Alpha L-Iduronidase Product Portfolio Table 77. Tega Therapeutics Inc Recent Developments Table 78. Global Alpha L-Iduronidase Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Table 79. Global Alpha L-Iduronidase Sales by Region (2021-2026) & (K Units) Table 80. Global Alpha L-Iduronidase Sales Market Share by Region (2021-2026) Table 81. Global Alpha L-Iduronidase Sales by Region (2027-2032) & (K Units) Table 82. Global Alpha L-Iduronidase Sales Market Share by Region (2027-2032) Table 83. Global Alpha L-Iduronidase Revenue by Region (2021-2026) & (US$ Million) Table 84. Global Alpha L-Iduronidase Revenue Market Share by Region (2021-2026) Table 85. Global Alpha L-Iduronidase Revenue by Region (2027-2032) & (US$ Million) Table 86. Global Alpha L-Iduronidase Revenue Market Share by Region (2027-2032) Table 87. North America Alpha L-Iduronidase Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 88. North America Alpha L-Iduronidase Sales by Country (2021-2026) & (K Units) Table 89. North America Alpha L-Iduronidase Sales by Country (2027-2032) & (K Units) Table 90. North America Alpha L-Iduronidase Revenue by Country (2021-2026) & (US$ Million) Table 91. North America Alpha L-Iduronidase Revenue by Country (2027-2032) & (US$ Million) Table 92. Europe Alpha L-Iduronidase Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 93. Europe Alpha L-Iduronidase Sales by Country (2021-2026) & (K Units) Table 94. Europe Alpha L-Iduronidase Sales by Country (2027-2032) & (K Units) Table 95. Europe Alpha L-Iduronidase Revenue by Country (2021-2026) & (US$ Million) Table 96. Europe Alpha L-Iduronidase Revenue by Country (2027-2032) & (US$ Million) Table 97. Asia Pacific Alpha L-Iduronidase Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 98. Asia Pacific Alpha L-Iduronidase Sales by Country (2021-2026) & (K Units) Table 99. Asia Pacific Alpha L-Iduronidase Sales by Country (2027-2032) & (K Units) Table 100. Asia Pacific Alpha L-Iduronidase Revenue by Country (2021-2026) & (US$ Million) Table 101. Asia Pacific Alpha L-Iduronidase Revenue by Country (2027-2032) & (US$ Million) Table 102. South America Alpha L-Iduronidase Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 103. South America Alpha L-Iduronidase Sales by Country (2021-2026) & (K Units) Table 104. South America Alpha L-Iduronidase Sales by Country (2027-2032) & (K Units) Table 105. South America Alpha L-Iduronidase Revenue by Country (2021-2026) & (US$ Million) Table 106. South America Alpha L-Iduronidase Revenue by Country (2027-2032) & (US$ Million) Table 107. Middle East and Africa Alpha L-Iduronidase Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 108. Middle East and Africa Alpha L-Iduronidase Sales by Country (2021-2026) & (K Units) Table 109. Middle East and Africa Alpha L-Iduronidase Sales by Country (2027-2032) & (K Units) Table 110. Middle East and Africa Alpha L-Iduronidase Revenue by Country (2021-2026) & (US$ Million) Table 111. Middle East and Africa Alpha L-Iduronidase Revenue by Country (2027-2032) & (US$ Million) Table 112. Global Alpha L-Iduronidase Sales by Type (2021-2026) & (K Units) Table 113. Global Alpha L-Iduronidase Sales by Type (2027-2032) & (K Units) Table 114. Global Alpha L-Iduronidase Sales Market Share by Type (2021-2026) Table 115. Global Alpha L-Iduronidase Sales Market Share by Type (2027-2032) Table 116. Global Alpha L-Iduronidase Revenue by Type (2021-2026) & (US$ Million) Table 117. Global Alpha L-Iduronidase Revenue by Type (2027-2032) & (US$ Million) Table 118. Global Alpha L-Iduronidase Revenue Market Share by Type (2021-2026) Table 119. Global Alpha L-Iduronidase Revenue Market Share by Type (2027-2032) Table 120. Global Alpha L-Iduronidase Price by Type (2021-2026) & (US$/Unit) Table 121. Global Alpha L-Iduronidase Price by Type (2027-2032) & (US$/Unit) Table 122. Global Alpha L-Iduronidase Sales by Application (2021-2026) & (K Units) Table 123. Global Alpha L-Iduronidase Sales by Application (2027-2032) & (K Units) Table 124. Global Alpha L-Iduronidase Sales Market Share by Application (2021-2026) Table 125. Global Alpha L-Iduronidase Sales Market Share by Application (2027-2032) Table 126. Global Alpha L-Iduronidase Revenue by Application (2021-2026) & (US$ Million) Table 127. Global Alpha L-Iduronidase Revenue by Application (2027-2032) & (US$ Million) Table 128. Global Alpha L-Iduronidase Revenue Market Share by Application (2021-2026) Table 129. Global Alpha L-Iduronidase Revenue Market Share by Application (2027-2032) Table 130. Global Alpha L-Iduronidase Price by Application (2021-2026) & (US$/Unit) Table 131. Global Alpha L-Iduronidase Price by Application (2027-2032) & (US$/Unit) Table 132. Key Raw Materials Table 133. Raw Materials Key Suppliers Table 134. Alpha L-Iduronidase Distributors List Table 135. Alpha L-Iduronidase Customers List Table 136. Alpha L-Iduronidase Industry Trends Table 137. Alpha L-Iduronidase Industry Drivers Table 138. Alpha L-Iduronidase Industry Restraints Table 139. Authors List of This Report List of Figures Figure 1. Research Methodology Figure 2. Research Process Figure 3. Key Executives Interviewed Figure 4. Alpha L-Iduronidase Product Image Figure 5. Global Alpha L-Iduronidase Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 6. Global Alpha L-Iduronidase Market Size (2021-2032) & (US$ Million) Figure 7. Global Alpha L-Iduronidase Sales (2021-2032) & (K Units) Figure 8. Global Alpha L-Iduronidase Average Price (US$/Unit) & (2021-2032) Figure 9. IDUA Product Image Figure 10. EC 3.2.1.76 Product Image Figure 11. Oncology Product Image Figure 12. Dermatology Product Image Figure 13. Immunology Product Image Figure 14. Musculoskeletal Disorders Product Image Figure 15. Global Alpha L-Iduronidase Revenue Share by Manufacturers in 2025 Figure 16. Global Manufacturers of Alpha L-Iduronidase, Manufacturing Sites & Headquarters Figure 17. Global Top 5 and 10 Alpha L-Iduronidase Players Market Share by Revenue in 2025 Figure 18. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 19. Global Alpha L-Iduronidase Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Figure 20. Global Alpha L-Iduronidase Sales by Region in 2025 Figure 21. Global Alpha L-Iduronidase Revenue by Region in 2025 Figure 22. North America Alpha L-Iduronidase Market Size by Country in 2025 Figure 23. North America Alpha L-Iduronidase Sales Market Share by Country (2021-2032) Figure 24. North America Alpha L-Iduronidase Revenue Market Share by Country (2021-2032) Figure 25. United States Alpha L-Iduronidase Revenue Growth Rate (2021-2032) & (US$ Million) Figure 26. Canada Alpha L-Iduronidase Revenue Growth Rate (2021-2032) & (US$ Million) Figure 27. Europe Alpha L-Iduronidase Market Size by Country in 2025 Figure 28. Europe Alpha L-Iduronidase Sales Market Share by Country (2021-2032) Figure 29. Europe Alpha L-Iduronidase Revenue Market Share by Country (2021-2032) Figure 30. Germany Alpha L-Iduronidase Revenue Growth Rate (2021-2032) & (US$ Million) Figure 31. France Alpha L-Iduronidase Revenue Growth Rate (2021-2032) & (US$ Million) Figure 32. U.K. Alpha L-Iduronidase Revenue Growth Rate (2021-2032) & (US$ Million) Figure 33. Italy Alpha L-Iduronidase Revenue Growth Rate (2021-2032) & (US$ Million) Figure 34. Netherlands Alpha L-Iduronidase Revenue Growth Rate (2021-2032) & (US$ Million) Figure 35. Asia Pacific Alpha L-Iduronidase Market Size by Country in 2025 Figure 36. Asia Pacific Alpha L-Iduronidase Sales Market Share by Country (2021-2032) Figure 37. Asia Pacific Alpha L-Iduronidase Revenue Market Share by Country (2021-2032) Figure 38. China Alpha L-Iduronidase Revenue Growth Rate (2021-2032) & (US$ Million) Figure 39. Japan Alpha L-Iduronidase Revenue Growth Rate (2021-2032) & (US$ Million) Figure 40. South Korea Alpha L-Iduronidase Revenue Growth Rate (2021-2032) & (US$ Million) Figure 41. India Alpha L-Iduronidase Revenue Growth Rate (2021-2032) & (US$ Million) Figure 42. Australia Alpha L-Iduronidase Revenue Growth Rate (2021-2032) & (US$ Million) Figure 43. China Taiwan Alpha L-Iduronidase Revenue Growth Rate (2021-2032) & (US$ Million) Figure 44. Southeast Asia Alpha L-Iduronidase Revenue Growth Rate (2021-2032) & (US$ Million) Figure 45. Southeast Asia Alpha L-Iduronidase Revenue Growth Rate (2021-2032) & (US$ Million) Figure 46. South America Alpha L-Iduronidase Market Size by Country in 2025 Figure 47. South America Alpha L-Iduronidase Sales Market Share by Country (2021-2032) Figure 48. South America Alpha L-Iduronidase Revenue Market Share by Country (2021-2032) Figure 49. Mexico Alpha L-Iduronidase Revenue Growth Rate (2021-2032) & (US$ Million) Figure 50. Brazil Alpha L-Iduronidase Revenue Growth Rate (2021-2032) & (US$ Million) Figure 51. Argentina Alpha L-Iduronidase Revenue Growth Rate (2021-2032) & (US$ Million) Figure 52. Middle East and Africa Alpha L-Iduronidase Market Size by Country in 2025 Figure 53. Middle East and Africa Alpha L-Iduronidase Sales Market Share by Country (2021-2032) Figure 54. Middle East and Africa Alpha L-Iduronidase Revenue Market Share by Country (2021-2032) Figure 55. Turkey Alpha L-Iduronidase Revenue Growth Rate (2021-2032) & (US$ Million) Figure 56. Saudi Arabia Alpha L-Iduronidase Revenue Growth Rate (2021-2032) & (US$ Million) Figure 57. UAE Alpha L-Iduronidase Revenue Growth Rate (2021-2032) & (US$ Million) Figure 58. Global Alpha L-Iduronidase Sales Market Share by Type (2021-2032) Figure 59. Global Alpha L-Iduronidase Revenue Market Share by Type (2021-2032) Figure 60. Global Alpha L-Iduronidase Price (US$/Unit) by Type (2021-2032) Figure 61. Global Alpha L-Iduronidase Sales Market Share by Application (2021-2032) Figure 62. Global Alpha L-Iduronidase Revenue Market Share by Application (2021-2032) Figure 63. Global Alpha L-Iduronidase Price (US$/Unit) by Application (2021-2032) Figure 64. Alpha L-Iduronidase Value Chain Figure 65. Alpha L-Iduronidase Production Mode & Process Figure 66. Direct Comparison with Distribution Share Figure 67. Distributors Profiles Figure 68. Alpha L-Iduronidase Industry Opportunities and Challenges

Scope & coverage.

Types
  • IDUA
  • EC 3.2.1.76
Applications
  • Oncology
  • Dermatology
  • Immunology
  • Musculoskeletal Disorders
Companies covered
  • ArmaGen Inc
  • BioStrategies LC
  • Denali Therapeutics Inc
  • EdiGene Inc
  • Gain Therapeutics Inc
  • Immusoft Corp
  • JCR Pharmaceuticals Co Ltd
  • Orchard Therapeutics Plc
  • Ossianix Inc
  • Rain Bio Inc
  • RegenxBio Inc
  • Tega Therapeutics Inc

Inside the report.

1 Preface
  1. 1.1 Scope of Report
  2. 1.2 Reasons for Doing This Study
  3. 1.3 Research Methodology
  4. 1.4 Research Process
  5. 1.5 Data Source
  6. 1.5.1 Secondary Sources
  7. 1.5.2 Primary Sources
2 Market Overview
  1. 2.1 Product Definition
  2. 2.2 Global Market Growth Prospects
  3. 2.2.1 Global Alpha L-Iduronidase Market Size (2021-2032)
  4. 2.2.2 Global Alpha L-Iduronidase Sales (2021-2032)
  5. 2.2.3 Global Alpha L-Iduronidase Market Average Price (2021-2032)
  6. 2.3 Alpha L-Iduronidase by Type
  7. 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
  8. 2.3.2 IDUA
  9. 2.3.3 EC 3.2.1.76
  10. 2.4 Alpha L-Iduronidase by Application
  11. 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
  12. 2.4.2 Oncology
  13. 2.4.3 Dermatology
  14. 2.4.4 Immunology
  15. 2.4.5 Musculoskeletal Disorders
3 Market Competitive Landscape by Manufacturers
  1. 3.1 Global Alpha L-Iduronidase Market Competitive Situation by Manufacturers (2021 Versus 2025)
  2. 3.2 Global Alpha L-Iduronidase Sales (K Units) of Manufacturers (2021-2026)
  3. 3.3 Global Alpha L-Iduronidase Revenue of Manufacturers (2021-2026)
  4. 3.4 Global Alpha L-Iduronidase Average Price by Manufacturers (2021-2026)
  5. 3.5 Global Alpha L-Iduronidase Industry Ranking, 2024 VS 2025 VS 2026
  6. 3.6 Global Manufacturers of Alpha L-Iduronidase, Manufacturing Sites & Headquarters
  7. 3.7 Global Manufacturers of Alpha L-Iduronidase, Product Type & Application
  8. 3.8 Global Manufacturers of Alpha L-Iduronidase, Established Date
  9. 3.9 Global Alpha L-Iduronidase Market CR5 and HHI
  10. 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
  1. 4.1 ArmaGen Inc
  2. 4.1.1 ArmaGen Inc Company Information
  3. 4.1.2 ArmaGen Inc Business Overview
  4. 4.1.3 ArmaGen Inc Alpha L-Iduronidase Sales, Revenue and Gross Margin (2021-2026)
  5. 4.1.4 ArmaGen Inc Alpha L-Iduronidase Product Portfolio
  6. 4.1.5 ArmaGen Inc Recent Developments
  7. 4.2 BioStrategies LC
  8. 4.2.1 BioStrategies LC Company Information
  9. 4.2.2 BioStrategies LC Business Overview
  10. 4.2.3 BioStrategies LC Alpha L-Iduronidase Sales, Revenue and Gross Margin (2021-2026)
  11. 4.2.4 BioStrategies LC Alpha L-Iduronidase Product Portfolio
  12. 4.2.5 BioStrategies LC Recent Developments
  13. 4.3 Denali Therapeutics Inc
  14. 4.3.1 Denali Therapeutics Inc Company Information
  15. 4.3.2 Denali Therapeutics Inc Business Overview
  16. 4.3.3 Denali Therapeutics Inc Alpha L-Iduronidase Sales, Revenue and Gross Margin (2021-2026)
  17. 4.3.4 Denali Therapeutics Inc Alpha L-Iduronidase Product Portfolio
  18. 4.3.5 Denali Therapeutics Inc Recent Developments
  19. 4.4 EdiGene Inc
  20. 4.4.1 EdiGene Inc Company Information
  21. 4.4.2 EdiGene Inc Business Overview
  22. 4.4.3 EdiGene Inc Alpha L-Iduronidase Sales, Revenue and Gross Margin (2021-2026)
  23. 4.4.4 EdiGene Inc Alpha L-Iduronidase Product Portfolio
  24. 4.4.5 EdiGene Inc Recent Developments
  25. 4.5 Gain Therapeutics Inc
  26. 4.5.1 Gain Therapeutics Inc Company Information
  27. 4.5.2 Gain Therapeutics Inc Business Overview
  28. 4.5.3 Gain Therapeutics Inc Alpha L-Iduronidase Sales, Revenue and Gross Margin (2021-2026)
  29. 4.5.4 Gain Therapeutics Inc Alpha L-Iduronidase Product Portfolio
  30. 4.5.5 Gain Therapeutics Inc Recent Developments
  31. 4.6 Immusoft Corp
  32. 4.6.1 Immusoft Corp Company Information
  33. 4.6.2 Immusoft Corp Business Overview
  34. 4.6.3 Immusoft Corp Alpha L-Iduronidase Sales, Revenue and Gross Margin (2021-2026)
  35. 4.6.4 Immusoft Corp Alpha L-Iduronidase Product Portfolio
  36. 4.6.5 Immusoft Corp Recent Developments
  37. 4.7 JCR Pharmaceuticals Co Ltd
  38. 4.7.1 JCR Pharmaceuticals Co Ltd Company Information
  39. 4.7.2 JCR Pharmaceuticals Co Ltd Business Overview
  40. 4.7.3 JCR Pharmaceuticals Co Ltd Alpha L-Iduronidase Sales, Revenue and Gross Margin (2021-2026)
  41. 4.7.4 JCR Pharmaceuticals Co Ltd Alpha L-Iduronidase Product Portfolio
  42. 4.7.5 JCR Pharmaceuticals Co Ltd Recent Developments
  43. 4.8 Orchard Therapeutics Plc
  44. 4.8.1 Orchard Therapeutics Plc Company Information
  45. 4.8.2 Orchard Therapeutics Plc Business Overview
  46. 4.8.3 Orchard Therapeutics Plc Alpha L-Iduronidase Sales, Revenue and Gross Margin (2021-2026)
  47. 4.8.4 Orchard Therapeutics Plc Alpha L-Iduronidase Product Portfolio
  48. 4.8.5 Orchard Therapeutics Plc Recent Developments
  49. 4.9 Ossianix Inc
  50. 4.9.1 Ossianix Inc Company Information
  51. 4.9.2 Ossianix Inc Business Overview
  52. 4.9.3 Ossianix Inc Alpha L-Iduronidase Sales, Revenue and Gross Margin (2021-2026)
  53. 4.9.4 Ossianix Inc Alpha L-Iduronidase Product Portfolio
  54. 4.9.5 Ossianix Inc Recent Developments
  55. 4.10 Rain Bio Inc
  56. 4.10.1 Rain Bio Inc Company Information
  57. 4.10.2 Rain Bio Inc Business Overview
  58. 4.10.3 Rain Bio Inc Alpha L-Iduronidase Sales, Revenue and Gross Margin (2021-2026)
  59. 4.10.4 Rain Bio Inc Alpha L-Iduronidase Product Portfolio
  60. 4.10.5 Rain Bio Inc Recent Developments
  61. 4.11 RegenxBio Inc
  62. 4.11.1 RegenxBio Inc Company Information
  63. 4.11.2 RegenxBio Inc Business Overview
  64. 4.11.3 RegenxBio Inc Alpha L-Iduronidase Sales, Revenue and Gross Margin (2021-2026)
  65. 4.11.4 RegenxBio Inc Alpha L-Iduronidase Product Portfolio
  66. 4.11.5 RegenxBio Inc Recent Developments
  67. 4.12 Tega Therapeutics Inc
  68. 4.12.1 Tega Therapeutics Inc Company Information
  69. 4.12.2 Tega Therapeutics Inc Business Overview
  70. 4.12.3 Tega Therapeutics Inc Alpha L-Iduronidase Sales, Revenue and Gross Margin (2021-2026)
  71. 4.12.4 Tega Therapeutics Inc Alpha L-Iduronidase Product Portfolio
  72. 4.12.5 Tega Therapeutics Inc Recent Developments
5 Global Alpha L-Iduronidase Market Scenario by Region
  1. 5.1 Global Alpha L-Iduronidase Market Size by Region: 2021 VS 2025 VS 2032
  2. 5.2 Global Alpha L-Iduronidase Sales by Region: 2021-2032
  3. 5.2.1 Global Alpha L-Iduronidase Sales by Region: 2021-2026
  4. 5.2.2 Global Alpha L-Iduronidase Sales by Region: 2027-2032
  5. 5.3 Global Alpha L-Iduronidase Revenue by Region: 2021-2032
  6. 5.3.1 Global Alpha L-Iduronidase Revenue by Region: 2021-2026
  7. 5.3.2 Global Alpha L-Iduronidase Revenue by Region: 2027-2032
  8. 5.4 North America Alpha L-Iduronidase Market Facts & Figures by Country
  9. 5.4.1 North America Alpha L-Iduronidase Market Size by Country: 2021 VS 2025 VS 2032
  10. 5.4.2 North America Alpha L-Iduronidase Sales by Country (2021-2032)
  11. 5.4.3 North America Alpha L-Iduronidase Revenue by Country (2021-2032)
  12. 5.4.4 United States
  13. 5.4.5 Canada
  14. 5.5 Europe Alpha L-Iduronidase Market Facts & Figures by Country
  15. 5.5.1 Europe Alpha L-Iduronidase Market Size by Country: 2021 VS 2025 VS 2032
  16. 5.5.2 Europe Alpha L-Iduronidase Sales by Country (2021-2032)
  17. 5.5.3 Europe Alpha L-Iduronidase Revenue by Country (2021-2032)
  18. 5.5.4 Germany
  19. 5.5.5 France
  20. 5.5.6 U.K.
  21. 5.5.7 Italy
  22. 5.5.8 Netherlands
  23. 5.6 Asia Pacific Alpha L-Iduronidase Market Facts & Figures by Country
  24. 5.6.1 Asia Pacific Alpha L-Iduronidase Market Size by Country: 2021 VS 2025 VS 2032
  25. 5.6.2 Asia Pacific Alpha L-Iduronidase Sales by Country (2021-2032)
  26. 5.6.3 Asia Pacific Alpha L-Iduronidase Revenue by Country (2021-2032)
  27. 5.6.4 China
  28. 5.6.5 Japan
  29. 5.6.6 South Korea
  30. 5.6.7 India
  31. 5.6.8 Australia
  32. 5.6.9 China Taiwan
  33. 5.6.10 Southeast Asia
  34. 5.7 South America Alpha L-Iduronidase Market Facts & Figures by Country
  35. 5.7.1 South America Alpha L-Iduronidase Market Size by Country: 2021 VS 2025 VS 2032
  36. 5.7.2 South America Alpha L-Iduronidase Sales by Country (2021-2032)
  37. 5.7.3 South America Alpha L-Iduronidase Revenue by Country (2021-2032)
  38. 5.7.4 Mexico
  39. 5.7.5 Brazil
  40. 5.7.6 Argentina
  41. 5.8 Middle East and Africa Alpha L-Iduronidase Market Facts & Figures by Country
  42. 5.8.1 Middle East and Africa Alpha L-Iduronidase Market Size by Country: 2021 VS 2025 VS 2032
  43. 5.8.2 Middle East and Africa Alpha L-Iduronidase Sales by Country (2021-2032)
  44. 5.8.3 Middle East and Africa Alpha L-Iduronidase Revenue by Country (2021-2032)
  45. 5.8.4 Turkey
  46. 5.8.5 Saudi Arabia
  47. 5.8.6 UAE
6 Segment by Type
  1. 6.1 Global Alpha L-Iduronidase Sales by Type (2021-2032)
  2. 6.1.1 Global Alpha L-Iduronidase Sales by Type (2021-2032) & (K Units)
  3. 6.1.2 Global Alpha L-Iduronidase Sales Market Share by Type (2021-2032)
  4. 6.2 Global Alpha L-Iduronidase Revenue by Type (2021-2032)
  5. 6.2.1 Global Alpha L-Iduronidase Sales by Type (2021-2032) & (US$ Million)
  6. 6.2.2 Global Alpha L-Iduronidase Revenue Market Share by Type (2021-2032)
  7. 6.3 Global Alpha L-Iduronidase Price by Type (2021-2032)
7 Segment by Application
  1. 7.1 Global Alpha L-Iduronidase Sales by Application (2021-2032)
  2. 7.1.1 Global Alpha L-Iduronidase Sales by Application (2021-2032) & (K Units)
  3. 7.1.2 Global Alpha L-Iduronidase Sales Market Share by Application (2021-2032)
  4. 7.2 Global Alpha L-Iduronidase Revenue by Application (2021-2032)
  5. 7.2.1 Global Alpha L-Iduronidase Sales by Application (2021-2032) & (US$ Million)
  6. 7.2.2 Global Alpha L-Iduronidase Revenue Market Share by Application (2021-2032)
  7. 7.3 Global Alpha L-Iduronidase Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
  1. 8.1 Alpha L-Iduronidase Value Chain Analysis
  2. 8.1.1 Alpha L-Iduronidase Key Raw Materials
  3. 8.1.2 Raw Materials Key Suppliers
  4. 8.1.3 Alpha L-Iduronidase Production Mode & Process
  5. 8.2 Alpha L-Iduronidase Sales Channels Analysis
  6. 8.2.1 Direct Comparison with Distribution Share
  7. 8.2.2 Alpha L-Iduronidase Distributors
  8. 8.2.3 Alpha L-Iduronidase Customers
9 Global Alpha L-Iduronidase Analyzing Market Dynamics
  1. 9.1 Alpha L-Iduronidase Industry Trends
  2. 9.2 Alpha L-Iduronidase Industry Drivers
  3. 9.3 Alpha L-Iduronidase Industry Opportunities and Challenges
  4. 9.4 Alpha L-Iduronidase Industry Restraints
10 Report Conclusion
    11 Disclaimer

      GET THE RESEARCH

      Choose your license.

      Choose who needs access.
      All options are for this report and research series.

      Compare access permissions.

      Single User License
      One named user. Individual access.
      Multi User License
      Up to 5 users in the same department.
      Enterprise License
      Organization-wide access within the agreed license.

      Access applies to the purchased edition. Later editions are separate purchases.

      License options
      $2,950USD
      Buy now

      PDF by email within 3–5 working days after payment confirmation.

      Talk to an analyst
      APO Research
      Talk to an analyst